Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma

Thyroid. 2017 Dec;27(12):1534-1543. doi: 10.1089/thy.2017.0290. Epub 2017 Nov 10.


Background: Anaplastic thyroid carcinoma (ATC), the most aggressive form of thyroid cancer, is unresponsive to radioiodine therapy. The current study aimed to extend the diagnostic and therapeutic application of radioiodine beyond the treatment of differentiated thyroid cancer by targeting the functional sodium-iodide symporter (NIS) to ATC.

Methods: The study employed nanoparticle vectors (polyplexes) based on linear polyethylenimine (LPEI), shielded by polyethylene glycol (PEG) and coupled to the synthetic peptide GE11 as an epidermal growth factor receptor (EGFR)-specific ligand in order to target a NIS-expressing plasmid (LPEI-PEG-GE11/NIS) to EGFR overexpressing human thyroid carcinoma cell lines. Using ATC xenograft mouse models, transfection efficiency by 123I scintigraphy and potential for systemic radioiodine therapy after systemic polyplex application were evaluated.

Results: In vitro iodide uptake studies in SW1736 and Hth74 ATC cells, and, for comparison, in more differentiated follicular (FTC-133) and papillary (BCPAP) thyroid carcinoma cells demonstrated high transfection efficiency and EGFR-specificity of LPEI-PEG-GE11/NIS that correlated well with EGFR expression levels. After systemic polyplex injection, in vivo 123I gamma camera imaging revealed significant tumor-specific accumulation of radioiodine in an SW1736 and an Hth74 xenograft mouse model. Radioiodine accumulation was found to be higher in SW1736 tumors, reflecting in vitro results, EGFR expression levels, and results from ex vivo analysis of NIS staining. Administration of 131I in LPEI-PEG-GE11/NIS-treated SW1736 xenograft mice resulted in significantly reduced tumor growth associated with prolonged survival compared to control animals.

Conclusions: The data open the exciting prospect of NIS-mediated radionuclide imaging and therapy of ATC after non-viral reintroduction of the NIS gene. The high tumor specificity after systemic application makes the strategy an attractive alternative for the treatment of highly metastatic ATC.

Keywords: EGFR targeting; anaplastic thyroid carcinoma; gene therapy; radioiodine; sodium–iodide symporter (NIS).

MeSH terms

  • Animals
  • Cell Line, Tumor
  • ErbB Receptors
  • Genetic Therapy
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Mice
  • Peptides
  • Symporters / metabolism*
  • Thyroid Carcinoma, Anaplastic / metabolism
  • Thyroid Carcinoma, Anaplastic / pathology
  • Thyroid Carcinoma, Anaplastic / therapy*
  • Thyroid Neoplasms / metabolism
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / therapy*


  • GE11 peptide
  • Iodine Radioisotopes
  • Iodine-131
  • Peptides
  • Symporters
  • sodium-iodide symporter
  • ErbB Receptors